May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Collagen-Based Gel as a Potential Transscleral Drug Delivery System for Age-Related Macular Degeneration
Author Affiliations & Notes
  • S. S. Potdar
    Rsch & Dvlpmt, Potentia Pharmaceuticals Inc, Louisville, Kentucky
  • F. Grossi
    Rsch & Dvlpmt, Potentia Pharmaceuticals Inc, Louisville, Kentucky
  • M. Singh
    Rsch & Dvlpmt, Potentia Pharmaceuticals Inc, Louisville, Kentucky
  • E. Sullivan
    Rsch & Dvlpmt, Potentia Pharmaceuticals Inc, Louisville, Kentucky
  • C. Vega
    Rsch & Dvlpmt, Potentia Pharmaceuticals Inc, Louisville, Kentucky
  • Z. Zhang
    Rsch & Dvlpmt, Potentia Pharmaceuticals Inc, Louisville, Kentucky
  • D. Devore
    Xium LLC, Woburn, Massachusetts
  • P. Deschatelets
    Rsch & Dvlpmt, Potentia Pharmaceuticals Inc, Louisville, Kentucky
  • C. Francois
    Rsch & Dvlpmt, Potentia Pharmaceuticals Inc, Louisville, Kentucky
  • P. Olson
    Rsch & Dvlpmt, Potentia Pharmaceuticals Inc, Louisville, Kentucky
  • Footnotes
    Commercial Relationships  S.S. Potdar, Potentia Pharmaceuticals Inc, E; F. Grossi, Potentia Pharmaceuticals Inc, E; M. Singh, Potentia Pharmaceuticals Inc, E; E. Sullivan, Potentia Pharmaceuticals Inc, E; C. Vega, Potentia Pharmaceuticals Inc, E; Z. Zhang, Potentia Pharmaceuticals Inc, E; D. Devore, Xium LLC, E; P. Deschatelets, Potentia Pharmaceuticals Inc, E; C. Francois, Potentia Pharmaceuticals Inc, E; P. Olson, Potentia Pharmaceuticals Inc, E.
  • Footnotes
    Support  NIH Grant EY017473
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 1816. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. S. Potdar, F. Grossi, M. Singh, E. Sullivan, C. Vega, Z. Zhang, D. Devore, P. Deschatelets, C. Francois, P. Olson; Collagen-Based Gel as a Potential Transscleral Drug Delivery System for Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2008;49(13):1816. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Age related macular degeneration (AMD) is a chronic inflammatory eye disease that gradually destroys sharp, central vision. With the introduction of novel anti-angiogenic agents, clinical treatment is currently possible only for the wet form of the disease and with frequent intravitreal injections. However, frequent intravitreal injection therapy carries a risk of complication and generates understandable issues of patient acceptability. There is a clear need for a delivery system that either bypasses the need for ocular injection or reduces its frequency to treat wet as well as dry AMD.

Methods: : Transcleral drug delivery provides a convenient way for delivering drug to the posterior segment of the eye. We tested rapidly polymerizing collagen-based slow release delivery system which is non-toxic, minimally invasive, and highly customizable towards different therapies. We examined this delivery system with POT-4, a strong complement inhibitor peptide currently in clinical trials for the treatment of AMD. In order to determine the optimum collagen formulation, we studied in-vitro release of POT-4 from different collagen formulations and tested whether POT-4 released from gel is still active. We also measured in-vitro release of POT-4 from a collagen gel for 6 weeks to ascertain the optimum collagen formulation. Pharmacokinetic studies are currently underway to study in-vivo release of POT-4 after transcleral injection of optimum collagen formulation mixed with POT-4.

Results: : Among the different collagen formulations tested, rapidly polymerizing collagen type I was the most promising formulation for POT-4 delivery. Release of POT-4 from collagen gel is bi-phasic with an initial burst followed by sustained release.

Keywords: age-related macular degeneration • development 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×